Presently, more than 110 drugs, in combination with prefilled syringes, are commercially available. Amongst these, close to 60% of the products target autoimmune disorders.

The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion ...

The global demand for Prefilled Syringe market in terms of revenue was worth of USD 1139.6 Million in 2020 and is expected to reach USD 2633.4 Million in 2027, growing at a CAGR of 8.95% from 2021 ...

The Food and Drug Administration (FDA) has approved a new 6mg single-dose prefilled syringe for Vabysmo ® (faricimab-svoa). Prior to this approval, Vabysmo had only been available in a single ...

When Vabysmo hit the market as the only bispecific antibody treatment for the eye, its major advantage was its dosing regimen, which could extend up to once every four months compared to every two ...

As Healio previously reported, the prefilled syringe was approved by the FDA in July. The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for three retinal conditions.

The prefilled syringe drug molecule market has seen significant evolution as healthcare systems globally strive for safer, more efficient drug delivery methods. Prefilled syringes offer an innovative ...